MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis.

Matrix metalloproteinase-3 or MMP3 also known as stromelysin-1 is an enzyme that is actively involved in joint destruction in rheumatoid arthritis (RA) patients. Screening the last three decades, it appears that serum levels of MMP3 reflect positively RA disease activity, joint and bone injury, and radiological erosion and predict disease outcome and drug responsiveness as summarized in several publications reporting outcomes on more than 8000 patients with RA. MMP-3 monitoring should be embedded in the routine assessment and accompany therapeutic modalities, in personalized medical RA management.

• Publication year

  2018

• Venue

  Baillière's Best Practice & Research : Clinical Rheumatology

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BERH.2019.01.006PMID 31174824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab

  2018cited by this paper
• Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.

  2018cited by this paper
• Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis

  2018cited by this paper
• Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis

  2018cited by this paper
• Association of heterogeneity of the thyroid gland with matrix metalloproteinase-3 in rheumatoid arthritis patients with Hashimoto's thyroiditis.

  2018cited by this paper
• Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage.

  2017cited by this paper
• The role of autoantibodies in the pathophysiology of rheumatoid arthritis

  2017cited by this paper
• Autoantibodies in inflammatory arthritis.

  2016cited by this paper
• [The application of matrix metalloproteinase-3 and 7 joints ultrasonic score in assessment of disease activity in patients with rheumatoid arthritis].

  2016cited by this paper
• [Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis].

  2016cited by this paper
• Therapeutic implications of autoantibodies in rheumatoid arthritis

  2016cited by this paper
• Performance of the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria for classification of rheumatoid arthritis in an Indian population: An observational study in a single centre

  2016cited by this paper
• Biomarkers in Rheumatoid Arthritis, what is new?

  2016cited by this paper
• Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score.

  2016cited by this paper
• MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy

  2016cited by this paper
• Baseline serum level of matrix metalloproteinase‐3 as a biomarker of progressive joint damage in rheumatoid arthritis patients

  2016cited by this paper
• Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab

  2016cited by this paper
• Rheumatoid arthritis-celiac disease relationship: joints get that gut feeling.

  2015cited by this paper
• Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients

  2015cited by this paper
• Elevated oxidative stress monitored via the albumin-thiol redox state is correlated with matrix metalloproteinase-3 elevation in patients with rheumatoid arthritis.

  2015cited by this paper
• Erratum to: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study

  2015cited by this paper
• Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study

  2015cited by this paper
• [MMP-3 as a Biomarker of Disease Activity of Rheumatoid Arthritis].

  2015cited by this paper
• Validation of the 2010-ACR/EULAR -classification criteria using newly EULAR-defined erosion for rheumatoid arthritis on the very early arthritis community-based (VErA) cohort.

  2015cited by this paper
• Serum Matrix Metalloproteinase-3 as a Noninvasive Biomarker of Histological Synovitis for Diagnosis of Rheumatoid Arthritis

  2014cited by this paper
• Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis?

  2014cited by this paper
• Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting

  2014cited by this paper
• Biomarkers for radiographic progression in rheumatoid arthritis.

  2014cited by this paper
• Weighting with the Lansbury articular index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients

  2014cited by this paper
• Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers

  2014cited by this paper
• The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases

  2014cited by this paper
• The new European League Against Rheumatism/American College of Rheumatology diagnostic criteria for rheumatoid arthritis: how are they performing?

  2013cited by this paper
• Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis.

  2013cited by this paper
• [Clinical value of serum matrix metalloproteinase-3 in evaluating joint destruction and therapeutic effect in rheumatoid arthritis patients].

  2013cited by this paper
• Rheumatoid arthritis--early diagnosis and disease management.

  2013cited by this paper
• Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA.

  2013cited by this paper
• Is rheumatoid factor useful in primary care? A retrospective cross-sectional study

  2013cited by this paper
• Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update

  2013cited by this paper
• Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis

  2013cited by this paper
• Performance of the American College of Rheumatology/European League Against Rheumatism 2010 criteria for the diagnosis of rheumatoid arthritis in Chinese patients.

  2013cited by this paper
• [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].

  2013cited by this paper
• The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis

  2013cited by this paper
• [Classification criteria for rheumatoid arthritis].

  2012cited by this paper
• The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria: is this still the same disease?

  2012cited by this paper
• Application of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in Korean patients with undifferentiated arthritis

  2012cited by this paper
• The Need to Better Classify and Diagnose Early and Very Early Rheumatoid Arthritis

  2012cited by this paper
• Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

  2012cited by this paper
• Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up

  2012cited by this paper
• Levels of Serum Matrix Metalloproteinase-3 Correlate with Disease Activity in the Enthesitis-related Arthritis Category of Juvenile Idiopathic Arthritis

  2011cited by this paper
• The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis.

  2011cited by this paper
• Diagnostic Accuracy of ACR/EULAR 2010 Criteria for Rheumatoid Arthritis in a 2-Year Cohort

  2011cited by this paper
• Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease?

  2011cited by this paper
• Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study

  2011cited by this paper
• Decrease of CD68 and MMP‐3 expression in synovium by treatment of adalimumab for rheumatoid arthritis

  2011cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• Rheumatoid arthritis

  2010cited by this paper
• Biomarkers of outcome in rheumatoid arthritis

  2010cited by this paper
• Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.

  2010cited by this paper
• High Serum Cartilage Oligomeric Matrix Protein Determines the Subset of Patients with Early-Stage Rheumatoid Arthritis with High Serum C-Reactive Protein, Matrix Metalloproteinase-3, and MRI-Proven Bone Erosion

  2009cited by this paper
• Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade

  2009cited by this paper
• Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level

  2009cited by this paper
• Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA

  2007cited by this paper
• Association of the 5A/6A Promoter Polymorphism of the MMP‐3 Gene with the Radiographic Progression of Rheumatoid Arthritis

  2007cited by this paper
• Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis.

  2007cited by this paper
• Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.

  2007cited by this paper
• Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis.

  2007cited by this paper
• [Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis].

  2007cited by this paper
• RF latex and anti-CCP antibodies: a combined strategy for diagnosing RA in primary care?

  2007cited by this paper
• Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers

  2007cited by this paper
• Meta-analysis: Diagnostic Accuracy of AntiCyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis

  2007cited by this paper
• Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.

  2007cited by this paper
• Matrix metalloproteinases: role in arthritis.

  2006cited by this paper
• 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3

  2006cited by this paper
• The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis.

  2006cited by this paper
• Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta.

  2005cited by this paper
• The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis

  2005cited by this paper
• Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.

  2005cited by this paper
• Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis

  2004cited by this paper
• Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome.

  2004cited by this paper
• Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis

  2004cited by this paper
• Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo

  2004cited by this paper
• Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.

  2004cited by this paper
• Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis.

  2003cited by this paper
• Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.

  2003cited by this paper
• Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis

  2003cited by this paper
• Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.

  2002cited by this paper
• [Usefulness of serum matrix metalloproteinase-3(MMP-3) level in the diagnosis of rheumatoid arthritis].

  2002cited by this paper
• Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

  2002cited by this paper
• Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study.

  2002cited by this paper
• Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.

  2001cited by this paper
• Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression.

  2000cited by this paper
• Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.

  2000cited by this paper
• Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not.

  2000cited by this paper
• High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis.

  2000cited by this paper
• Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.

  2000cited by this paper
• Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.

  1999cited by this paper
• Matrix Metalloproteinases*

  1999cited by this paper
• Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis.

  1999cited by this paper
• Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.

  1998cited by this paper
• Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.

  1997cited by this paper

• Antibody-conjugated mesenchymal stromal cell drug delivery system for the treatment of autoimmune diseases in mice

  2026cites this paper
• In silico degradomics reveals disease- and endotype-specific alterations in the joint tissue landscape

  2026cites this paper
• Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target.

  2025cites this paper
• 程氏蠲痹汤通过阻断WTAP-Wnt7b-Wnt/β-catenin信号轴抑制类风湿性关节炎病理

  2025cites this paper
• Integrated analysis of the relationship between metabolic pathways and immune infiltration in rheumatoid arthritis

  2025cites this paper
• The Association Between Three MMP3 Gene Polymorphisms and the Efficacy of Platelet-Rich Plasma Therapy in the Treatment of Lateral Elbow Tendinopathy—A Prospective Cohort Study

  2025cites this paper
• A clinically applicable method for early interstitial lung disease detection in incident rheumatoid arthritis cases: integration of protein biomarkers and clinical factors

  2025cites this paper
• Contemporary approaches to the management of rheumatoid arthritis: precision and progress.

  2025cites this paper
• In vivo anti-rheumatoid arthritis activity and mechanistic insights of methanol extract of Zanthoxylum usambarense Engl.

  2025cites this paper
• The impact of alpha-lipoic acid treatment on various mediators of inflammatory and immune responses in a murine arthritis model

  2025cites this paper
• Direct Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-Related Amyloidosis

  2025cites this paper
• Identification of Matrix Metalloproteinase 3 as a Potential Biomarker for Dry Eye Disease

  2025cites this paper
• Uncovering the molecular targets of phytocannabinoids: mechanistic insights from inverse molecular docking fingerprint approaches

  2025cites this paper
• A review on animal venom-based matrix metalloproteinase modulators and their therapeutic implications.

  2025cites this paper
• Ubiquitin specific peptidase 13 protects against inflammation-associated joint injury in collagen-induced rheumatoid arthritis mice by targeting TRAF6.

  2025cites this paper
• Precision Medicine in Rheumatology: The Role of Biomarkers in Diagnosis and Treatment Optimization

  2025cites this paper
• Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis

  2025cites this paper
• The SERPINB4 gene mutation identified in twin patients with Crohn’s disease impaires the intestinal epithelial cell functions

  2025cites this paper
• The relationship between autoimmune diseases and temporomandibular disorders: A study combined with the GEO database

  2025cites this paper
• Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes: A Narrative Review.

  2024cites this paper
• Sinomenine ameliorates fibroblast-like synoviocytes dysfunction by promoting phosphorylation and nuclear translocation of CRMP2.

  2024cites this paper
• Circ_0011058 alleviates RA pathology through the circ_0011058/miR-335-5p/CUL4B signal axis

  2024cites this paper
• circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway

  2024cites this paper
• Metalloproteomic Analysis of Hemophilic Arthropathy Synovial Tissue: Insights into Metal Overload and Pathogenesis.

  2024cites this paper
• Plasma gelsolin and matrix metalloproteinase-3 levels as diagnostic markers for psoriatic arthritis

  2024cites this paper
• Higher Serum Level of MMP-3 and Homocysteine in Patients Admitted With COVID-19

  2024cites this paper
• Chromone components of Saposhnikovia divaricate attenuates rheumatoid arthritis development by inhibiting inflammatory response.

  2024cites this paper
• Proxy endpoints - bridging clinical trials and real world data

  2024cites this paper
• Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis

  2024cites this paper
• Single-Cell Multi-Dimensional data analysis reveals the role of ARL4C in driving rheumatoid arthritis progression and Macrophage polarization dynamics.

  2024cites this paper
• Galectin-3, Matrix Metalloproteinase-3 and TLR-2 Receptor as Novel Biomarkers in the Diagnosis of Rheumatoid Arthritis

  2024cites this paper
• Matrix metalloproteinases-3 (MMP-3) serum level and genetic polymorphisms associated with rheumatoid arthritis

  2024cites this paper
• A network-based framework to discover treatment-response-predicting biomarkers for complex diseases.

  2024cites this paper
• Investigating the characteristics of mild intervertebral disc degeneration at various age stages using single-cell genomics

  2024cites this paper
• The emerging role of the semaphorin family in cartilage and osteoarthritis

  2024cites this paper
• Cold Air Plasma Inhibiting Tumor-Like Biological Behavior of Rheumatoid Arthritis Fibroblast-Like Synovial Cells via G2/M Cell Cycle Arrest

  2024cites this paper
• Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review

  2024cites this paper
• Vascular dysfunction in sporadic bvFTD: white matter hyperintensity and peripheral vascular biomarkers

  2024cites this paper
• Fibroblast-like synoviocytes orchestrate daily rhythmic inflammation in arthritis

  2024cites this paper
• The FTO-CMPK2 Pathway in Fibroblast-like Synoviocytes Modulates Rheumatoid Arthritis Synovial Inflammation and Cartilage Homeostasis via mtDNA Regulation

  2024cites this paper
• Matrix Metalloproteinase-Responsive Drug Delivery Systems.

  2023cites this paper
• Clinical effect and biological mechanism of exercise for rheumatoid arthritis: A mini review

  2023cites this paper
• The Effective Treatment of Purpurin on Inflammation and Adjuvant-Induced Arthritis

  2023cites this paper
• Clinical association study on the matrix metalloproteinase expression in the serum of patients with connective tissue disease complicated with interstitial lung disease

  2023influential citation
• A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis

  2023cites this paper
• Bioresponsive Cytokine Delivery Responding to Matrix Metalloproteinases.

  2023cites this paper
• Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis

  2023cites this paper
• A negative feedback bionic hydrogel reverses damaged cartilage microenvironment and induces targeted BMSCs differentiation for cartilage regeneration

  2023cites this paper
• Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis

  2023cites this paper
• Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms

  2023cites this paper
• Analysis of factors associated with abnormal thyroid function among medical staff in radiotherapy departments

  2023cites this paper
• TMT-Based Proteomics Analysis of Senescent Nucleus Pulposus from Patients with Intervertebral Disc Degeneration

  2023cites this paper
• What do osteoporosis and osteoarthritis have in common？An integrated study of overlapping differentially expressed genes in bone mesenchymal stem cells of osteoporosis and osteoarthritis.

  2023cites this paper
• PREDICTION OF INFLAMMATION IN HEMODIALYSIS PATIENTS USING NEURAL NETWORK ANALYSIS

  2023cites this paper
• Complement factor H attenuates TNF-α-induced inflammation by upregulating EIF3C in rheumatoid arthritis

  2023cites this paper
• Wilforine inhibits rheumatoid arthritis pathology through the Wnt11/β-catenin signaling pathway axis

  2023cites this paper
• Supplementary management of symptomatic hand osteoarthritis with Pycnogenol®.

  2023cites this paper
• Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3

  2022cites this paper
• Supplementing clinical diagnostics of erosive joint diseases with bio-inspired ratiometric sensors

  2022cites this paper
• Changes in perioperative C-reactive protein levels in patients with rheumatoid arthritis undergoing total knee arthroplasty in the biologic era

  2022cites this paper
• АЦЦП-негативный ревматоидный артрит — клинические и иммунологические особенности

  2022cites this paper
• ACCP-negative rheumatoid arthritis – clinical and immunological features

  2022cites this paper
• Current status and prospects of IL-6–targeting therapy

  2022cites this paper
• Central Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis

  2022cites this paper
• How to Model Rheumatoid Arthritis in Animals: From Rodents to Non-Human Primates

  2022cites this paper
• Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia

  2022cites this paper
• Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis

  2022cites this paper
• An estrogen-sensitive fibroblast population drives abdominal muscle fibrosis in an inguinal hernia mouse model

  2022cites this paper
• Adenosine inhibits TNFα-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling

  2022cites this paper
• Global Proteomic Analyses Reveals Abnormal Immune Regulation in Patients With New Onset Ankylosing Spondylitis

  2022influential citation
• Functional Impairment and Periodontitis in Rheumatoid Arthritis

  2022cites this paper
• Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium

  2022cites this paper
• Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity

  2022cites this paper
• Rheumatoid arthritis chondrocytes produce increased levels of pro-inflammatory proteins

  2022cites this paper
• Inflammation-related pathways involved in damaged articular cartilage of rats exposed to T-2 toxin based on RNA-sequencing analysis

  2022cites this paper
• Lipopolysaccharide induces inflammatory microglial activation through CD147-mediated matrix metalloproteinase expression

  2022cites this paper
• Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

  2022cites this paper
• Use of some bone-related cytokines as predictors for rheumatoid arthritis severity by neural network analysis

  2022cites this paper
• Hypoxia inducible factor-1α mediates the mechanism of the Hedgehog pathway in tendinopathy repair by Asperosaponin VI

  2022influential citation
• The mechanism of the anti-inflammatory effect of Oldenlandia diffusa on arthritis model rats: a quantitative proteomic and network pharmacologic study

  2022cites this paper
• The effect of long non-coding RNAs in joint destruction of rheumatoid arthritis

  2022cites this paper
• ACPA-negative rheumatoid arthritis: From immune mechanisms to clinical translation

  2022cites this paper
• LncRSPH9-4 Facilitates Meningitic Escherichia coli-Caused Blood–Brain Barrier Disruption via miR-17-5p/MMP3 Axis

  2021cites this paper
• Adenosine inhibits TNFα-induced MMP-3 Production in MH7A RA Synoviocytes via A2A Receptor Signaling

  2021influential citation
• Dissecting the Molecular Mechanism of Wang-Bi Capsule in the Treatment of Experimental Rheumatoid Arthritis Based on Synovial Tissue Proteomic Analysis

  2021cites this paper
• Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications

  2021cites this paper
• MicroRNA-497 Reduction and Increase of Its Family Member MicroRNA-424 Lead to Dysregulation of Multiple Inflammation Related Genes in Synovial Fibroblasts With Rheumatoid Arthritis

  2021cites this paper
• Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis

  2021cites this paper
• Expression of mBD4, mBD3 and CRAMP during type II collagen-induced arthritis/CIA and their association with inflammation and bone-remodeling markers.

  2021cites this paper
• NOX2-Deficient Neutrophils Facilitate Joint Inflammation Through Higher Pro-Inflammatory and Weakened Immune Checkpoint Activities

  2021cites this paper
• POS0489 DOES TIME TO REMISSION DIFFER DEPENDING ON ROUTE OF ADMINISTRATION OF METHOTREXATE IN AN EARLY ARTHRITIS TREAT TO TARGET (T2T) COHORT?

  2021cites this paper
• Serum Metalloprotease 3 (MMP-3) biomarker of therapeutic efficacy during treatment of rheumatoid arthritis.

  2021cites this paper
• Exosomes Isolated From Bone Marrow Mesenchymal Stem Cells Exert a Protective Effect on Osteoarthritis via lncRNA LYRM4-AS1-GRPR-miR-6515-5p

  2021cites this paper
• Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial

  2021cites this paper
• Activity of fibroblast-like synoviocytes in rheumatoid arthritis was impaired by dickkopf-1 targeting siRNA

  2020influential citation
• Proteomic analysis of human synovial fluid reveals potential diagnostic biomarkers for ankylosing spondylitis

  2020cites this paper
• Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway

  2020cites this paper
• Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19

  2020cites this paper
• SLUG is Enhanced by Chemotherapeutics and Functions to Promote Invasion and Metastasis by Directly Targeting MMP3 in Cervical Cancer

  2020cites this paper
• Inhibition of BMP3 increases the inflammatory response of fibroblast-like synoviocytes in rheumatoid arthritis

  2020cites this paper